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Other names: ACVRII; ACVR2A; Activin Receptor, 
type 2A; Activin Receptor A type 2; T ACTRII;    
ActR-II 
Location: 2q22.3 
Local order: Genes flanking ACVR2A, in centromere 
to telomere direction on 2q22, are:  
PAPBPCP2 2q22.3 - polyadenylate binding protein, 
cytoplasmic, pseudogene 2. 
ACVR2 2q22.3 - activin receptor type IIA. 
ORC4L 2q23.1 - origin recognition complex, subunit 4. 
DNA/RNA 
Description 
ACVR2 gene spans a region of 85,796 bp and has 11 
exons. Exon lengths are 180, 208, 110, 155, 144, 144, 
146, 115, 139, 131 and 3745 base pairs. Exon 10 
contains a polyadenine tract that may be mutated in 
microsatellite unstable cells. 
Transcription 
The transcript is 5217 base pairs. 
Protein 
Description 
ACVR2 is a member of the transforming growth factor 
beta (TGF-b) receptor family. It is a 70-75kDA protein 
consisting of 513 amino acids. It is a transmembrane 
receptor for activin, with a cysteine-rich extracellular 
ligand-binding domain, a single pass transmembrane 
domain, and an intracellular domain with constitutive 
serine/threonine kinase activity. 
Upon binding activin, ACVR2 associates with and 
phosphorylates ACVR1. 
ACVR1, in turn, phosphorylates Smad2 and/or Smad3. 
Phosphorylated Smad2 and Smad3 associate with 
Smad4, translocate to the nucleus, and regulate gene 
expression. 
There may be other non-Smad pathways in activin 
signal transduction. These include the RhoA-ROCK-
MEKK1-JNK and MEKK1-p38 pathways. 
In addition to activin, other ligands such as myostatin, 
nodal, and bone morphogenetic protein 7 (BMP-7) may 
also bind to ACVR2 and affect signal transduction. 
Expression 
Abundant expression in multiple tissues, including 
skeletal muscle, stomach, heart, endometrium, testes, 
prostate, ovary, and neural tissues. The cell surface 
level of ACVR2 and ACVR2B is regulated by proteins 
called ARIPs (activin receptor-interacting proteins). 
Localisation 
Cell surface, spanning cytoplasmic membrane. 
Function 
Activin signaling via its receptors has roles in cell 
proliferation, differentiation, apoptosis, metabolism, 




Exon 10 polyadenine tract (A8-A7). 
Implicated in 
Colon cancer 
Note: Colon cancer with A8-A7 deletion in exon10. 
Disease 
Microsatellite unstable colon cancer. 
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Prognosis 
Increased tumor size. 
Abnormal Protein 
No fusion protein; truncated non-functional protein. 
Oncogenesis 
Occurs late in adenoma to carcinoma transition. 
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